Condition:   Gallbladder Neoplasms
Intervention:   Drug: Somatostatin
Sponsors:   Shanghai Jiao Tong University School of Medicine;   Xuanwu hospital capital medical university;   Beijing friendship hospital affiliate of capital university of medical sciences;   Peking University First Hospital;   Tianjin Medical University Cancer Institute and Hospital;   First affiliated hospital of Dalian medical university;   The First Hospital of China Medical University;   The first clinical college of harbin medical university;   The 2nd affiliated hospital of harbin medical university;   Shengjing hospital of china medical university;   China-Japan union hospital of jilin university;   The people’s hospital of Heilongjiang province;   Eastern Hepatobiliary Surgery Hospital;   Shanghai Changzheng Hospital;   Shandong Provincial Hospital;   Qilu hospital of Shandong university;   Xijing hospital of The fourth military medical university;   Tangdu hospital of The fourth military medical university;   Qinghai povince people’s hospital;   Qinghai university affiliated hospital;   The first affiliated hospital, Chongqing medical university;   Daping hospital of the third military medical university;   Kungming the first people’s hospital;   Lanzhou university second hospital;   Xi'an Center Hospital;   The first people’s hospital of Guiyang;   Southwest hospital of the third military medical university;   Xinqiao hospital of the third military medical university;   The first affiliated hospital of kunming medical college;   The second affliated hospital of kunming medical college
Recruiting - verified October 2009

Condition:   Cholangiocarcinoma
Intervention:   Drug: Gemcitabine, Capecitabine and Bevacizumab
Sponsors:   Roswell Park Cancer Institute;   Genentech
Recruiting - verified February 2010

Condition:   Carcinoid Syndrome
Intervention:   Drug: BIM 23A760
Sponsor:   Ipsen
Recruiting - verified February 2010

Condition:   Primary Sclerosing Cholangitis
Intervention:  
Sponsor:   Mayo Clinic
Recruiting - verified February 2010

Conditions:   Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Peritoneal Cavity Cancer;   Small Intestine Cancer
Interventions:   Drug: palonosetron hydrochloride;   Other: placebo
Sponsors:   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
Recruiting - verified February 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: adjuvant therapy;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Procedure: quality-of-life assessment
Sponsor:   NCIC Clinical Trials Group
Active, not recruiting - verified March 2010

Conditions:   Cholangiocarcinoma Cancer;   Gallbladder Cancer;   Pancreatic Cancer;   Ampullary Cancer
Interventions:   Drug: Gemcitabine and Docetaxel (Chemotherapy);   Radiation: XRT at 5040 or 5400 cGy and 5FU (Radiation and Chemotherapy);   Drug: Gemcitabine and Docetaxel (Chemotherapy)
Sponsor:   Washington University School of Medicine
Recruiting - verified February 2010

Condition:   Cancer
Interventions:   Drug: fentanyl sublingual spray;   Other: questionnaire administration
Sponsor:   Insys Therapeutics Inc
Recruiting - verified October 2008

Condition:   Solid Tumors
Interventions:   Drug: AMG 706;   Drug: AMG 706;   Drug: AMG 706
Sponsor:   Amgen
Completed - verified February 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions:   Drug: capecitabine;   Other: clinical observation;   Procedure: adjuvant therapy
Sponsor:   Southampton University Hospitals NHS Trust
Recruiting - verified March 2008

Condition:   Cancer
Interventions:   Drug: isolated perfusion;   Drug: melphalan
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2009

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Intervention:   Drug: bortezomib
Sponsors:   Fox Chase Cancer Center;   National Cancer Institute (NCI)
Active, not recruiting - verified February 2010

Condition:   Cancer
Interventions:   Drug: docetaxel;   Drug: thalidomide
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Intervention:   Drug: erlotinib hydrochloride
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Completed - verified May 2004

Condition:   Cancer
Interventions:   Drug: dexamethasone;   Drug: ondansetron;   Procedure: quality-of-life assessment
Sponsor:   NCIC Clinical Trials Group
Completed - verified March 2010

Conditions:   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Intervention:   Drug: becatecarin
Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
Completed - verified February 2010